Shares of Aligos Therapeutics Inc (NASDAQ:ALGS) rose 3.1% on Wednesday after the company provided a progress update on its ...

Explore the potential of bacteriophages as a breakthrough therapy against bacterial infections amidst rising antibiotic resistance.

– Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – “We are pleased to highlight ...

– Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – SOUTH SAN FRANCISCO, Calif., Nov ...

The global medical community has long sought an effective cure for hepatitis B, one of the world’s most persistent viral infections. Assembly Biosciences may have moved significantly closer to this ...

dDepartment of Severe Hepatopathy, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China eDepartment of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical ...

Assembly Biosciences, Inc. (NASDAQ:ASMB) is one of the growth stocks that could double by 2027. On June 25, the company announced positive topline results from its Phase 1b trial of ABI-4334, a capsid ...

School of Ecological Engineering, Guizhou University of Engineering Science, Bijie, China Parvoviruses are a group of single-stranded DNA viruses that lack an envelope and are widely distributed in ...

– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort – – Mean plasma HBV DNA reductions of 3.2 ...